Cortechs.ai leads discussion on Actionable Intelligence at the 2018 Radiological Society of North America meeting amidst NeuroQuant 3.0 Release.
(SAN DIEGO) — Kelly Leyden, Product Manager at Cortechs.ai, presented at the Machine Learning Showcase on the third day of the largest radiology conference in the world, Radiological Society of North America’s (RSNA) annual meeting. Leyden described the evolution of machine learning and artificial intelligence algorithms developed by Cortechs.ai with a timeline of products and imaging tools used in day-to-day radiology practice.
Leyden was followed by CorTech’s strategic partner, HealthLytix’s Chief Operating Officer Ajit Shankaranarayanan. Both spoke of the paradigm shift occurring within patient care, one that is less focused on treatment and more focused on prevention.
Quantitative imaging is a powerful tool that can aid in preventative medicine by supplementing clinical history, physical exams, lab tests, and more. Incorporating imaging biomarkers with genetics and other clinical and demographic data can predict the risk of developing diseases such as Alzheimer’s.
Shankaranarayanan demonstrated the integration of HealthLytix’s Polygenic Hazard Score with NeuroQuant volumetric data, to provide a precise prediction of a patient’s Alzheimer’s Disease risk. The information allows the physician to weigh the benefits of administering future tests and informs the patient of potential decisions they may need to make to ensure lifelong care. Intelligent integration of individual biomarkers elevates the utility and value of each measure, creating intelligence that is actionable.
The release of NeuroQuant 3.0 will aid these predictions through enhanced visualizations of longitudinal change in volumes as well as lesions, providing precise MRI physics informed quantitative data, and personalized outputs for physicians. The machine learning derived Dynamic AtlasTM provides a patient-specific age and sex-matched atlas, allowing for the most precise and personalized volumetric segmentation.
Artificial intelligence continues to advance quantitative imaging and drive the development of action-oriented clinical solutions. Cortechs.ai prioritizes the functionality of its algorithm using physics, biology, and physiology, incorporating prior knowledge when possible, and working with vendors to optimize protocols. NeuroQuant® is the first application of its kind for clinical use, designed with input from neurologists to provide more accessible data. Through the machine learning derived Dynamic AtlasTM and normative database, the company provides the most accurate and expansive reference data on the market
About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. Please visit cortechs.ai for further information.
###
Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai
